NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2022 Earnings Conference Call May 16, 2022 8:30 AM ET

Company Participants

Robert Besthof – Interim Chief Executive Officer, Head of Operations & Chief Commercial Officer

Tom Johnson – Investor Relations

Ira Strassberg – Chief Financial Officer and Treasurer

Conference Call Participants

Operator

Greetings and welcome to NRX Pharmaceuticals First Quarter 2022, Earnings Conference Call. At this time, all participants are in listen-only mode. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Tom Johnson from Investor Relations. Sir, please go ahead.

Tom Johnson

Thank you, Operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call or forward-looking statements under U.S. Federal Securities Law. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call's speak only as of date hereof. And the company undertakes no obligation to update or revise the forward-looking statements. Information presented on this call is contained in the press release issued earlier today. And then the company's Form 10-Q that we're filing today, which will be accessed from the investor's page of the NRX Pharmaceuticals website. Joining me on today's call from NRX Pharmaceuticals are Robert Besthof, Interim Chief Executive Officer, and Ira Strassberg Chief Financial Officer and Treasurer. Robert will provide a summary of the company's progress during -- before turning it over to Ira for review the company's financial results. Following their prepared remarks, the management team will address investor questions. I'll now turn the call over to Robert.

Robert Besthof

Thank you, Tom. Good morning, everyone and thank you for joining us today. We appreciate your attendance and look forward to summarizing our progress on our strategic priorities that are guiding our work in 2022. So let's begin. On our previous Year-End Earnings Call, we announced our new strategic focus for 2022 by concentrating on our two late-stage drug candidates. NRX-10 1 for the treatment of severe bipolar depression with acute and sub-acute suicidality, aviation and behavior for which we have reactivated Clinical Cloud development as part of our psychiatry portfolio. ZYESAMI in its intravenous formulation for the treatment of critical COVID-19 and potentially other respiratory diseases. We believe these two drug candidates have shown solid scientific evidence to potentially help patients in these areas of very high unmet needs and conserve as platform for numerous indications in other respiratory and psychiatric conditions. Congruent with our strategy to shift treatment paradigms, both drugs could fill significant therapeutic gaps. NRX-101 could become the first oral drug for bipolar depression in patients with acute and sub-acute suicidality.